Table 3.
Characteristics of patients studied after 6 cycles with Ra-223
| Patient | Mean SUVmax (Range) | Mean SUVmax (Range) [% of baseline] After 3 cycles* | Mean SUVmax (Range) [% of baseline] After 6 cycles** | PSA (ng/ml) | ALP (UI/L) | LDH (UI/L) | VAS | Hb (g/dl) | Plt (× 103/µL) | Neutrophils (× 103/µL) | Leukocytes (× 103/µL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 91.6 (79.1-144.1) | 63.3 (45.4-99.1) [69.1%] | 58.1 (40.7-70.3) [63.4%] | 0.6 | 70 | 145 | 4 | 12.5 | 216 | 3.7 | 4.9 |
| 2 | 66.8 (26.9-84.2) | 49.3 (18.9-69.7) [73.8%] | 19.9 (14.4-49.0) [30%] | 5.7 | 129 | 148 | 2 | 13.1 | 202 | 4 | 5.5 |
| 3 | 58.7 (22.5-76.4) | 40.2 (17.2-54) [68.5%] | 17.3 (4.1-28.8) [29.5%] | 0.13 | 49 | 120 | 1 | 13.1 | 300 | 3.3 | 4.7 |
| 4 | 81.7 (33.1-91.9) | 73.0 (28.6-80.1) [89.3%] | 38.7 (14.8-66.2) [47.4%] | 1.3 | 53 | 230 | 1 | 13.1 | 277 | 3.9 | 6.3 |
| 5 | 69.1 (36.9-101.2) | 52.9 (31.0-89.7) [76.5%] | 27.3 (14.4-49.9) [39.5%] | 1.2 | 119 | 85 | 2 | 9.7 | 188 | 2.5 | 4.1 |
| 6 | 89.7 (53.1-101.6) | 70.5 (42.1-88.8) [78.6%] | 66.9 (38.7-80.9) [74.6%] | 0.9 | 101 | 113 | 2 | 9.9 | 283 | 3.4 | 3.9 |
| 7 | 96.6 (84.7-155.0) | 95.3 (88.3-141.1) [98.6%] | 90.9 (80.7-131.7) [94.1%] | 2.4 | 120 | 134 | 4 | 8.8 | 209 | 2.9 | 2.9 |
*
Percentage of declined Mean SUVmax after 3 cycles of Ra-223.
**
Percentage of declined Mean SUVmax after 6 cycles of Ra-223.